The Discontinuation Gap

Medicine was built for initiation, not discontinuation.

There is a clear protocol for starting a patient on an opioid. There is no equivalent for stopping one.

Across pain medicine, psychiatry, primary care, and addiction medicine, every prescriber has felt this gap. We were trained on indication, mechanism, dose-finding. We were not trained on how to bring a patient back down.

So discontinuation happens in the margins of the visit — eyeballed percentages, copied from the last patient, written on a sticky note. When it works, no one notices. When it doesn't, patients destabilize. They withdraw. They relapse. They return to a higher dose, or worse, a different drug.

The literature is now substantial. The gap is not closed.

Over the last five years, the published evidence on what happens when tapering is done badly has become unmistakable. Agnoli and colleagues documented a 68% increase in overdose risk and a near-doubling of mental-health crisis events among patients tapered from stable long-term opioid therapy. Fenton's long-term follow-up showed those elevated risks persist for at least two years after taper initiation. Hallvik's Oregon Medicaid cohort found that abrupt discontinuation significantly increased suicide risk and pushed some patients toward heroin. In 2025, Yang and colleagues reported that even slow tapering can be associated with increased all-cause mortality in older adults.

The regulatory response caught up. The FDA's 2019 drug safety communication required new labeling on opioid analgesics emphasizing gradual, individualized tapering. The HHS Guide for Clinicians provides a structured eight-area framework for tapering decisions. The 2022 CDC Clinical Practice Guideline walked back the misinterpretation of the 2016 guideline and emphasized patient-centered, slow tapers. The VA/DoD's 2022 clinical practice guideline went further, formally recommending buprenorphine over full-agonist opioids for long-term therapy.

So the evidence is settled. The guidelines have caught up. The labels have been changed.

The gap remains open anyway.

The operational gap specifically

The distance between taper slowly and individually as a principle and this dose, on this date, in this formulation, mapped to this refill cycle as a prescription is the gap that has not been closed.

A clinician in a 15-minute follow-up visit, looking at a stable patient on a long-standing regimen, does not lack guidance about whether a taper might be appropriate. They lack a workflow for executing the taper safely if it is. The CDC tells them what good tapering looks like in the abstract. The HHS Guide tells them what good tapering looks like as a process. Neither document tells them which available formulation to write today, on which date, with which interval, in what quantity, with what real-time signal that the chosen rate is or is not aligned with the evidence.

This is the gap that, as of 2026, still produces the harms the literature has documented.

The landscape has changed. The gap has not.

The prescription-opioid crisis has substantially abated since 2022. Drug overdose deaths in the United States fell from over 108,000 in 2022 to roughly 79,000 in 2024. Opioid-involved deaths dropped from approximately 83,000 in 2023 to around 55,000 in 2024. And of those remaining opioid deaths, 88% now involve illicit fentanyl rather than prescription opioids.

That is good news. It also changes the question.

The patients still on long-term prescription opioid therapy in 2026 are an increasingly selected, often older, often stable cohort. Many of them should not be tapered at all — Fenton's 2022 Comparative Effectiveness study found no benefit from tapering stable long-term opioid patients without evidence of misuse. For those who should be tapered or transitioned — because their clinical situation has changed, because a partial-agonist pathway is safer, because the patient has decided together with their clinician that a reduction makes sense — the operational gap is exactly where those decisions live or fail.

The mission is no longer to reduce prescribing volume. The mission is to ensure that the small number of taper and transition decisions that still happen, happen well.

What closing the gap actually looks like

Closing the discontinuation gap is not another guideline. The guidelines exist. It is not another conference. The conferences happen. It is not another study documenting harm. The studies have been done.

Closing the gap is the operational infrastructure that lets every guideline already on the books do the work it was written to do — at the prescribing moment, inside the workflow a clinician actually uses, mapped to the formulations actually available in the pharmacy, aligned with the refill cycles that govern the real patient encounter.

That infrastructure does not exist yet. Pieces of it exist — the Washington State AMDG calculator, Oregon's BRAVO framework, individual EHR-specific SmartSets. But a clinical decision-support layer purpose-built for structured, individualized, evidence-aligned medication discontinuation, extensible across every taper-sensitive medication class, does not exist in American medicine today.

That is the work we are doing. Reducere is one piece of that work, scoped to opioid tapering as the starting wedge. The platform behind it is designed for every medication class where the same gap exists — benzodiazepines, antidepressants, antipsychotics, gabapentinoids. Any class where stopping is harder than starting.

This is the work of a generation

Medicine was built for initiation, not discontinuation. The discontinuation gap survived the crisis that produced it. Closing it is the work of the next decade, and it will take all of us — clinicians, researchers, health systems, policymakers, and the patients still carrying the weight of medication regimens their original prescribers never planned for them to leave.

We are building toward that future with structure, safety, and science. We would welcome collaboration from anyone else doing the same.